New investment from EQT Life Sciences and OrbiMed with participation from existing investors MinervaX will hold financial reserves of more than €125 million, following the financing The financing...
Full enrolment and dosing commenced with its novel, prophylactic GBS vaccine in both healthy older adults and older adult population with co-morbidities First immunological read-outs are anticipated...
Expands development of novel GBS vaccine in older adult population Targeting significant and growing unmet medical need of GBS infection Copenhagen, Denmark, 17 April 2023 – MinervaX ApS, a...
Newly appointed CMO with more than 25 years’ experience in vaccine development Fast Track status granted by US Food and Drug Administration Completion of enrolment of its 2nd phase II clinical trial...
Financing from new investors Trill Impact Ventures and Pureos Bioventures as well as existing investors Backing from European Investment Bank Planning for Phase 3 clinical development of novel GBS...
Copenhagen, Denmark, 20 September 2022 – MinervaX, a privately held Danish biotechnology company today announces that EMA has awarded PRIME status for its vaccine against Group B Streptococcus...
Completed enrolment of all pregnant women in a Phase 2 study in South Africa and UgandaFollowing clearance from the US FDA, Danish Medicines Agency and UK MRHA, started enrolment of pregnant women...
Completed enrolment of 150 pregnant women in a Phase 2 study in South Africa and dosing started in an additional 50 pregnant women in Uganda, as part of same studyPhase 1 booster study started in...
MinervaX raises upsized EUR 47.4M (USD 57M) Series B to advance its novel Group B Streptococcus vaccine through mid-stage clinical trials On the back of highly promising Phase Ib data, MinervaX has...
MinervaX announces award of 4.4 million euro in investment from Novo Holding's repair impact fund and Sunstone Life Science Ventures for further clinical development of the company's vaccine against...
MinervaX initiates phase I clinical trial with innovative Group B Streptococcal (GBS) vaccine to prevent life-threatening infections in newborns. Novel, single component vaccine predicted to protect...
Group B Streptococcal vaccine for the prevention of life-threatening infections in newborns secures funding to reach clinical proof of concept. MinervaX, a privately held Danish biotech company,...
